PMID- 29239031
OWN - NLM
STAT- MEDLINE
DCOM- 20180806
LR  - 20180806
IS  - 1365-2559 (Electronic)
IS  - 0309-0167 (Linking)
VI  - 72
IP  - 1
DP  - 2018 Jan
TI  - Molecular alterations of neuroendocrine tumours of the lung.
PG  - 142-152
LID - 10.1111/his.13394 [doi]
AB  - Neuroendocrine tumours of the lung comprise low [typical carcinoid (TC)], 
      intermediate [atypical carcinoid (AC)] and high-grade [small-cell lung cancer 
      (SCLC) and large-cell neuroendocrine carcinoma (LCNEC)] malignancies, while a 
      pre-invasive lesion [diffuse idiopathic pulmonary neuroendocrine cell hyperplasia 
      (DIPNECH)] may generate a subset of peripheral carcinoid tumours. These neoplasms 
      are differentiated conventionally based on mitotic rate, presence of necrosis and 
      cytological details, according to the 2015 World Health Organisation (WHO) 
      classification. Clinical data and molecular alterations distinguish carcinoids 
      and high-grade carcinomas into two separate categories. Previous studies have 
      demonstrated a significantly higher rate of chromosomal aberrations in carcinomas 
      (e.g. 3p and 17p deletions), but restriction of multiple endocrine neoplasia type 
      1 (MEN1) mutations to carcinoids. High-grade carcinomas are also characterised by 
      TP53 and RB1 gene inactivation. In this review, a critical analysis of the 
      diagnostic and prognostic role of Ki67 labelling index and a concise discussion 
      of the most relevant findings regarding molecular characterisation of lung 
      neuroendocrine neoplasms are reported. In addition, we illustrate how the 
      development of promising therapeutic strategies based on the identification of 
      molecular targets (mTOR inhibitors in carcinoids and targeting of the Notch 
      ligand DLL3 in SCLC) may require the assessment of predictive biomarkers, even in 
      the group of neuroendocrine tumours of the lung.
CI  - (c) 2017 John Wiley & Sons Ltd.
FAU - Rossi, Giulio
AU  - Rossi G
AD  - Pathology Unit, Azienda USL Valle d'Aosta, Regional Hospital 'Parini', Aosta, 
      Italy.
FAU - Bertero, Luca
AU  - Bertero L
AUID- ORCID: 0000-0001-9887-7668
AD  - Department of Oncology, University of Turin and Pathology Unit, AOU Citta della 
      Salute e della Scienza, Torino, Italy.
FAU - Marchio, Caterina
AU  - Marchio C
AD  - Department of Medical Sciences, University of Turin and Pathology Unit, AOU Citta 
      della Salute e della Scienza, Torino, Italy.
FAU - Papotti, Mauro
AU  - Papotti M
AD  - Department of Oncology, University of Turin and Pathology Unit, AOU Citta della 
      Salute e della Scienza, Torino, Italy.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Histopathology
JT  - Histopathology
JID - 7704136
RN  - 0 (Biomarkers, Tumor)
SB  - IM
MH  - Biomarkers, Tumor/*genetics
MH  - Humans
MH  - Lung Neoplasms/*genetics/*pathology
MH  - Neuroendocrine Tumors/*genetics/*pathology
OTO - NOTNLM
OT  - carcinoid
OT  - immunohistochemistry
OT  - lung
OT  - neuroendocrine
OT  - sequencing
EDAT- 2017/12/15 06:00
MHDA- 2018/08/07 06:00
CRDT- 2017/12/15 06:00
PHST- 2017/06/02 00:00 [received]
PHST- 2017/09/01 00:00 [revised]
PHST- 2017/09/05 00:00 [accepted]
PHST- 2017/12/15 06:00 [entrez]
PHST- 2017/12/15 06:00 [pubmed]
PHST- 2018/08/07 06:00 [medline]
AID - 10.1111/his.13394 [doi]
PST - ppublish
SO  - Histopathology. 2018 Jan;72(1):142-152. doi: 10.1111/his.13394.